User:RajeRaje/sandbox

Tetulomab (HH1) is a murine monoclonal antibody for cancer treatment. It is developed by Erlend Smeland and Steinar Funderud at the Norwegian Radium Hospital.[1] Tetulomab binds to the glycoprotein CD37 on the surface of mature malignant and non-malignant human B cells and can therefore be used as a tumor-targeting carrier for radioactive and cytotoxic payloads for treatment of hematological cancer.[1-3] The Norwegian biotech company Nordic Nanovector a.s has exclusive commercial therapeutic use of Tetulomab and has patented the radioimmunotherapeutic use of Tetulomab against CD37. Tetulomab is the tumor-targeting carrier in the product candidate Betalutin, a radioimmunoconjugate currently being tested in patients with relapsed or refractory low-grade non-Hodgkin’s lymphoma through a Phase I/II clinical trial sponsored by Nordic Nanovector a.s.